known profibrogenic mediators expressed by activated HSCs include transforming growth factor beta (TGF-b) and platelet-derived growth factor, whereas HGF functions as an antifibrogenic mediator. 2, 3 Although the effects of HGF in reducing accumulation of ECM and development of hepatic fibrosis have been well studied, the exact mechanism regulating HGF expression in HSCs in response to liver injury and inflammation remains unknown.
CYLD is a deubiquitination enzyme acting as a tumor suppressor in different types of cancer. 4 Deubiquitin activity of CYLD interferes with components of distinct signaling pathways, thereby regulating different cellular processes, such as proliferation and survival. [5] [6] [7] CYLD is down-regulated in hepatocellular carcinoma (HCC), and forced expression of CYLD in HCC cell lines triggers a significant decrease in nuclear factor kappa B (NF-jB) activity. 8, 9 A recent study demonstrated that deletion of CYLD exon 9 generates a deubiquitinase-deficient form of CYLD, which causes hepatic inflammation, fibrosis, and cancer. 10 The phenotype of these mice reflects elevated TGF-b1-activated kinase 1 (TAK1) ubiquitination and Jun N-terminal kinase (JNK) activation caused by lack of CYLD-mediated cleavage of polyubiquitin chains from TAK1. 10 Another recent study showed that deletion of CYLD exon 7/8, a short splice variant of CYLD, leads to biliary fibrosis and increased susceptibility for chemically induced HCC. 11 Despite these important findings, the current knowledge about the CYLD-mediated signaling pathway that ameliorates hepatocellular damage and liver fibrogenesis is limited.
Histone acetylation (HAC) is associated with active gene transcription and histone deacetylation with transcriptional repression. Acetylation status of histones is controlled through opposing actions of two classes of enzymes: histone acetyltransferases (HATs), which transfer acetyl groups to lysine residues within the N-terminal tails of core histones, and histone deacetylases (HDACs), which remove the acetyl groups. 12, 13 Generally, HAC loosens the structure of chromatin, facilitates access of the transcriptional machinery to DNA, and initiates gene transcription. 12 In contrast, HDACs remove acetyl groups from histone proteins and reverse the effects of HATs through alterations in transcription. 13 To date, 18 human HDACs have been identified and grouped into four classes. HDAC7 is a member of a class of HDACs that shuttle between the cytoplasm and nuclei. HDAC7 suppresses expression of the angiogenesis suppressor gene, A kinase anchor protein 12, 14 Nuclear factor of activated T cells, cytoplasmic 1, 15 c-jun, 16 and the cell-cycle inhibitor gene, Reprimo. 17 More recently, it was shown that forced accumulation of HDAC7 in the nucleus of cytotoxic T cells suppresses expression of genes encoding cytokines, cytokine receptors, and adhesion molecules. 18 The function of HDACs, including HDAC7, is blocked using HDAC inhibitors (HDACi). These compounds interact with the catalytic domain of HDACs and alter gene expression. HDACi reduce expression of inflammatory and fibrotic genes, thereby exhibiting strong antifibrotic characteristics in the liver. In these studies, treatment with HDACi inhibited HSC activation and reduced liver fibrosis. [19] [20] [21] However, the HDAC target of HDACi in reducing HSC activation has not been identified.
In the present study, we observed that, upon hepatic injury, cylindromatosis (CYLD) regulates expression of hepatocyte growth factor (HGF) through direct interactions that prevent HDAC7 recruitment to the promoter of HGF. Elevated levels of HGF in the presence of CYLD reduced hepatocellular death and hepatic fibrosis.
Materials and Methods
Cells and Cell Culture. Primary murine hepatocytes and primary murine and human HSCs were isolated and cultured as previously described. [22] [23] [24] In vitro HSC activation was achieved through cell culture on uncoated tissue-culture dishes as previously described. 23, 24 Animals and Experimental Murine Models of Hepatic Injury. Generation of CYLD KO (knockout; CYLD 2/2 ) mice has previously been described. 25 Mice were maintained in specific pathogen-free housing at the Clinical Research Center (Malm€ o, Sweden) and at the University Hospital Regensburg (Regensburg, Germany), and animal experiments were performed according to national and international guidelines of the European Union (EU). At the age of 10-12 weeks, male C57BL/6 WT (wild-type; CYLD
1/1
) and CYLD 2/2 mice underwent different models of acute liver injury (ALI) and CLI (5-6 animals per group). For short-term studies of hepatocellular injury and inflammation, diethylnitrosamine (DEN; Sigma-Aldrich, St. Louis, MO) was intraperitoneally (IP) injected (100 lg/g body weight [b.w.]), and animals were sacrificed at the indicated time points. CCl 4 -induced ALI was analyzed 24 hours after IP injection of 1 lL of CCl 4 /g b.w. (diluted with corn oil). Galactosamine hydrochloride (GalN) plus tumor necrosis factor (TNF)-induced ALI were analyzed 6 hours after IP injection of 1 mg of GalN/g b.w. and ). In addition, bile duct ligation (BDL) or sham operations were performed as previously described, 26 and animals were sacrificed at 3 weeks after the operation. A nonalcoholic steatohepatitis (NASH)-inducing methionine-and cholinedeficient diet (MCD diet) or control diet was fed for 6 weeks. The MCD diet was purchased from MP Biomedicals (Solon, OH); all other chows were purchased from Ssniff (Soest, Germany). To assess the effect of recombinant HGF on DEN-mediated liver injury in CYLD 2/2 mice, a single IP injection of recombinant murine HGF (1.68 lg/kg; R&D Systems, Abingdon, UK) or vehicle (PBS) was administered to CYLD 2/2 mice. Twenty-four hours later, an IP injection with DEN (100 mg/kg b.w.) was administered together with an intravenous HGF or vehicle (PBS) application. All mice were sacrificed through heart puncture under deep ketamine/xylazine (2:1) anesthesia, and liver tissue and blood samples were collected for further analyses.
Human Tissue Specimens. Formalin-fixed, paraffin-embedded human liver tissues for immunohistochemical (IHC) analysis were retrieved from the surgical pathology files of the Institute of Pathology of the University of Regensburg. Human liver tissue for cell isolation and expression analyses was obtained according to the guidelines of the charitable statecontrolled foundation, Human Tissue and Cell Research (Regensburg, Germany). Informed consent was obtained from all patients, and the study was approved through the local ethics committee of the University of Regensburg.
Statistical Analyses. Statistical analyses were performed using GraphPad Prism5 software (GraphPad Software Inc., San Diego, CA). Results are expressed as the means 6 standard error (range) or percent. Two-tailed P values were calculated using MannWhitney's U test. A correlation analysis was performed using Pearson's product-moment correlation coefficient. A P value <0.05 was considered statistically significant.
Additional Methods. Detailed methodology is described in the Methods section of the Supporting Information.
Results
CYLD Deficiency Aggravates Hepatocellular Damage, Inflammation, and Fibrosis in Response to ALI and CLI. CYLD is ubiquitously expressed in human and murine livers (Supporting Fig. 1A ), but mice lacking the CYLD gene 25 exhibited regular liver architecture and hepatocellular integrity under physiological conditions (Supporting Fig. 1B-E) . To understand the role of CYLD under pathophysiological conditions, we exposed WT (CYLD 5 ). To simulate chronic hepatic injury, we used 3-week BDL, an established model of extrahepatic cholestasis in rodents. 26 Similar to the DEN and CCl 4 models, we observed a marked up-regulation of hepatic CYLD expression in control mice ( Fig. 2A) . In the BDL model, CYLD 2/2 mice showed more hepatocellular damage (Fig. 2B,C) , increased levels of proinflammatory genes, and inflammatory cell markers ( Fig. 2D and Supporting Fig. 6 ), compared to CYLD 1/1 mice.
Furthermore, we applied a second model of CLI, in which we fed mice an MCD diet, causing NASH. In this model, CYLD deficiency did not affect triglyceride levels in liver and serum (Supporting Fig. 7 ), but exacerbated hepatocellular damage and inflammation (Supporting Fig. 8 ). Moreover, CLI induced higher hepatic expression levels of profibrogenic genes ( , mice (Fig. 2F) . In both models, CYLD 2/2 and CYLD 1/1 control mice (fed with control diet or sham operated) showed similar levels of proinflammatory and -fibrogenic gene expression, and neither CYLD 2/2 nor CYLD 1/1 mice revealed significant infiltration with inflammatory or apoptotic cells in liver (Supporting Figs. 8 and 9 ).
Next, we compared JNK and TAK activation in CYLD 2/2 and CYLD 1/1 mice using CCl 4 and GalN/ TNF treatment. We did not observe any significant differences in JNK and TAK activation comparing nontreated hepatocytes isolated from CYLD 2/2 and CYLD 1/1 mice (Supporting Fig. 10A ). In GalN/TNFtreated liver and hepatocytes, we detected elevated JNK activation in CYLD 10B ).
CYLD Expression Is Increased in Activated HSCs. Hepatic injury results in activation of the HSCs, which is characterized by de novo expression of alpha-smooth muscle actin (a-SMA). 2, 3 In ALI and CLI models, enhanced hepatic a-SMA expression in CYLD 2/2 mice, compared to CYLD 1/1 mice, was reflecting more advanced HSC activation (Fig. 3A) and IHC confirmed an increased number of a-SMApositive cells in chronically injured CYLD
, liver tissue (Fig. 3B) . In contrast, neither CYLD 2/2 nor CYLD 1/1 mice showed significant HSC activation under nontreated conditions (Supporting Fig. 11 ). Notably, a striking correlation between CYLD and a-SMA expression was observed in hepatic tissue from patients with chronic liver disease (CLD; Fig. 3C ). IHC analysis revealed similar CYLD-staining intensity of hepatocytes in control and cirrhotic human liver tissues (Supporting Fig. 12 ), but a strong CYLD immunosignal in a-SMA-positive cells in fibrotic septa of cirrhotic human livers (Fig. 3D) . Double immunofluorescence (IF) analysis confirmed colocalization of CYLD and a-SMA in cirrhotic liver tissue (Fig. 3E) . Moreover, in an in vitro model of HSC activation, we observed that activated HSCs (day 7) expressed higher levels of CYLD than quiescent HSCs (day 2; Fig. 3F ), and CYLD expression in activated HSCs was further induced in response to TNF stimulation (Fig. 3G) . Together, these findings indicated that CYLD expression is inducible during HSC activation and in response to proinflammatory cytokine stimulation.
The Functional Role of CYLD in Activated HSCs. To obtain further insight into the role of CYLD in HSCs, we suppressed CYLD expression in activated human HSCs and observed that expression of CYLD interfered with activation of the classic NF-jB pathway (Fig. 4A) and expression of NF-jB target genes, such as monocyte chemoattractant protein 1 (MCP-1), intracellular adhesion molecule 1 (ICAM-1), and interleukin (IL)-6 (Fig. 4B) , which are up-regulated during HSC activation. 2 In contrast, and unexpectedly, CYLD suppression in activated HSCs reduced expression of HGF (Fig. 4C) , but not expression of other growth factors in human HSCs (Supporting Fig. 13A ).
To validate these findings, we isolated HSCs from CYLD 1/1 and CYLD 2/2 mice. Activation of murine CYLD 2/2 HSCs revealed enhanced expression of NFjB-regulated pro-inflammatory genes, compared to WT cells (Supporting Fig. 13B ) and electrophoresis mobility shift assay analysis confirmed enhanced NF-jB binding activity in TNF-stimulated CYLD 2/2 HSCs, compared to CYLD 1/1 HSCs (Supporting Fig. 14A ). In contrast, we found no differences in activation of TAK1 and JNK comparing CYLD 2/2 and CYLD 1/1 HSCs (Supporting Fig. 14B) . Liver tissues or quiescent HSCs isolated from CYLD 1/1 and CYLD 2/2 mice revealed no significant differences in HGF expression under noninduced conditions (Supporting Fig. 15A,B) . In contrast, hepatic HGF expression was significantly lower in CYLD 2/2 than in 
CYLD
1/1 mice in models of DEN-or CCl 4 -induced liver injury (Fig. 4D,E and Supporting Fig. 15C ), similar to the HGF expression in activated HSCs isolated from CYLD 2/2 and CYLD 1/1 mice (Fig. 4F,G) . In contrast, expression of other growth factors was either similar or enhanced (Supporting Fig. 13C,D) . These data indicate CYLD as a critical regulator of HGF in activated HSCs. Effect of CYLD-Mediated HGF Regulation in Activated HSCs. Activated HSCs are the major source of hepatic HGF, which plays a critical role in tissue protection and regeneration and provides less susceptibility to chronic inflammation and fibrosis. [27] [28] [29] [30] To characterize the effect of reduced HGF expression on hepatocellular damage in CYLD-deficient HSCs, we incubated primary hepatocytes, isolated from CYLD 1/1 mice, with conditioned medium (CM) from activated HSCs derived from CYLD 1/1 or CYLD 2/2 mice, before treatment with DEN. This procedure promoted caspase-3/7 activity, which was significantly higher in hepatocytes stimulated with CM from CYLD
2/2
, compared with those treated with CM from CYLD 1/1 HSCs (Fig. 5A) . Inhibition of HGF downstream signaling, after addition of neutralizing anti-HGF antibody (Ab), enhanced DENinduced caspase-3/7 activity in hepatocytes treated with CM from CYLD 1/1 HSCs, but not in hepatocytes incubated with CM from CYLD 2/2 HSCs (Fig.  5A, left panel) . Conversely, supplementation with recombinant HGF did not affect caspase-3/7 activity in hepatocytes incubated with CM from CYLD
1/1
HSCs, but alleviated DEN-induced caspase-3/7 activity in hepatocytes treated with CM from CYLD
2/2
HSCs (Fig. 5A, right panel) . Next, we assessed whether exogenous HGF ameliorates hepatocellular injury in CYLD-deficient mice. Injection of recombinant HGF into CYLD 2/2 mice before acute DENinduced hepatic injury significantly reduced hepatic cell death (Fig. 5B) , proinflammatory gene expression (Supplorting Fig. F16A ), inflammatory cell recruitment (Fig. 5C) , and profibrogenic gene expression ( Fig. 5D; Supporting Fig. 16B ). The potent activity of HGF in preventing cell death in distinct types of cells, including hepatocytes, is typically mediated through activation of protein kinase B (Akt).
31-33 DEN treatment markedly increased activation of Akt in CYLD
, hepatic tissue (Fig.  5E) . Furthermore, in CYLD-deficient mice, injection of HGF before DEN treatment elevated activation of Akt (Fig. 5E,F) . In CYLD 1/1 mice, HGF application did not significantly affect apoptosis, proinflammatory and -fibrogenic gene expression, or Akt activation (Supporting Fig. 17 ). Taken together, these results suggest that lower HGF levels in CYLD-deficient mice result in pronounced hepatic injury, inflammation, and profibrogenic gene expression, associated with the development and progression of hepatic injury.
CYLD Regulates HGF Levels in HSCs Through Interaction With HDAC7. Next, we identified the mechanisms through which CYLD induces HGF expression in HSCs. The cytokines, IL-6 and TNF, primarily secreted from activated Kupffer cells (KCs) in response to hepatic injury, stimulate HGF production in HSCs. 34, 35 Both cytokines promoted HGF expression and secretion in HSCs isolated from CYLD 1/1 mice, but not in CYLD-deficient HSCs (Fig. 6A) . Furthermore, luciferase assays demonstrated substantially increased HGF promoter activity after CYLD transfection (Fig. 6B) , indicating that CYLD regulates expression of HGF at the transcriptional level. HDACs balance the acetylation activities of HACs during chromatin remodeling. HDACs are essential in regulating gene transcription, and inhibition of these enzymes suppresses HGF expression in tumor stroma. 36 To determine whether the repression of HGF in the absence of CYLD is dependent on histone acetylation, HSCs were treated with the potent HDACi, trichostatin A (TSA) or trapoxin (TPX). This treatment generated an increase of HGF levels in both WT and CYLD-deficient HSCs (Fig. 6C,D) . HDAC7 is a member of the HDAC class IIa enzymes, possessing nucleocytoplasmic shuttling properties. 37 It was recently shown that TNF derepresses expression of HDAC7 target genes. 38 To determine whether CYLD regulates HDAC7 in HSCs, thereby affecting HGF production, we overexpressed CYLD and observed that CYLD overrode HDAC7-mediated inhibition of HGF promoter activity (Fig. 6E) and overexpression of HDAC7 inhibited TNF-or IL6-induced HGF expression (Fig. 6F) . Furthermore, IL-6 and TNF stimulation reduced nuclear translocation of HDAC7 (Fig. 7A) and its recruitment to the promoter of HGF (Fig. 7B) in WT, but not in CYLD-deficient, HSCs (Fig. 7A,B) . DNA immunoprecipitation assay confirmed direct binding of HDAC7 to the HGF promoter (Supporting Fig. 18 ). Most important, knocking down HDAC7 expression using small interfering RNA (siRNA) or short hairpin RNA resulted in elevated levels of HGF messenger RNA (mRNA) in both CYLD 1/1 and CYLD
HSCs (Fig. 7C) . In addition, overexpression of the shuttling-deficient HDAC7 mutant (HDAC7-mNES) prevented induction of HGF in CYLD 1/1 HSCs (Fig.  7D) . Thus, interaction of CYLD with HDAC7 in the cytoplasm in response to IL-6 or TNF stimulation might reflect reduced nuclear translocation and recruitment to the HGF promoter. Endogenous immunoprecipitation and colocalization studies showed that, in nonstimulated CYLD 1/1 HSCs, HDAC7 was primarily localized in nuclei, whereas stimulation with TNF promoted translocation of HDAC7 from the nucleus to the cytoplasm (Fig. 7E, upper panels) . In contrast, HDAC7 was constitutively localized in the nucleus of CYLD 2/2 HSCs in the absence or presence of TNF (Fig. 7E, lower panels) . Furthermore, intense cytoplasmic colocalization (Fig. 7E ) and an association (Fig.  7F ) between HDAC7 and CYLD were detected in stimulated cells. However, total levels of HDAC7 did not differ between nonstimulated and stimulated cells (Fig. 7F) .
Overexpression of a catalytic mutant version of CYLD (CYLD-C/S) blocked HDAC7 nuclear localization, suggesting that deubiquitinating activity of CYLD is not responsible for blocking the nuclear localization of HDAC7 after IL-6 or TNF stimulation (Fig. 8A) . Furthermore, FLAG pull-down assays, using a series of CYLD deletion mutants, showed that a construct containing the third CAP-Gly domain and the proline-rich region of CYLD (CYLD 222-956) interacted with purified HDAC7 (Fig.8 B,C) . These results suggest that IL-6 and TNF promote the binding of HDAC7 to CYLD while blocking nuclear translocation and recruitment of HDAC7 to the HGF promoter. However, in the absence of CYLD, HDAC7 mediates the down-regulation of HGF expression, which promotes hepatocellular damage, inflammation, and fibrosis in response to hepatic injury.
Discussion
Deubiquitination is a highly regulated process implicated in different signaling pathways, and mutations in several deubiquitination enzymes have been linked to acute and chronic inflammatory diseases. CYLD is a deubiquitination enzyme acting as a tumor suppressor in different types of human cancer, including HCC. 8, 39 CYLD has previously been shown to affect mechanisms associated with acute and chronic hepatic injury. 10, 11 In these studies, mice with a hepatocyte-specific expression of a deubiquitinasedeficient form of CYLD or mice with deletion of CYLD's TRAF2-binding site (exon 7/8 deleted) suffered from hepatic inflammation, fibrosis, and cancer through uncontrolled TAK1 and JNK activation. 10, 11 In contrast to these findings, complete deletion of CYLD in the present study did not affect the number of apoptotic cells, liver damage, or inflammation under noninducing conditions. These phenotypic differences may be explained by CYLD deletion being complete in our study while only partial in previous studies. 10, 11 Here, we have uncovered a novel mechanism by which CYLD expression in HSCs protects from hepatic injury independently of its deubiquitin activity.
An underlying cause of the hepatoprotective and antifibrogenic effects of CYLD is the regulatory function of this protein on HGF, a pleiotropic signaling molecule expressed and secreted through activated HSCs. Especially in injured liver tissue, activation of HGF is promoted by factors secreted from hepatocytes, which further protects hepatocytes from cellular damage and inhibits hepatic fibrosis. [40] [41] [42] Hepatic HGF expression was significantly lower in CYLD 2/2 than in CYLD 1/1 mice upon hepatic injury, and exogenous application of HGF rescued the liver injury phenotype observed in CYLD-deficient mice. This treatment resulted in reduced hepatic cell death and elevated activation and phosphorylation of Akt. In this pathway, cell survival by HGF is mediated through signaling from its receptor, c-Met, to phosphatidylinositol 3-kinase and the phosphorylation of Akt. 43 Akt, in turn, exerts antiapoptotic effects through phosphorylation of B-cell lymphoma 2-associated death promoter and procaspase-9, which promotes cell survival. [31] [32] [33] Taken together, these results suggest that CYLDinduced HGF production inhibits hepatic injury and cell death associated with development and progression of hepatic fibrosis.
As a mechanism through which CYLD induces HGF expression in HSCs, we identified the interaction of HGF with HDAC7. HDAC7 belongs to the HDAC class IIa enzymes, possessing nucleocytoplasmic shuttling properties. 37 It was shown recently that 14-3-3 and Ca
21
/calmodulin-dependent kinase (CaMK) I control the subcellular localization of HDAC-7. CaMK I-mediated phosphorylation of HDAC7 stimulates HDAC7 export from the nucleus, and in the cytoplasm, HDAC7 directly interacts with 14-3-3 proteins, leading to the derepression of HDAC7 target genes. 37 Here, we showed that deletion of the HDAC7 gene in HSCs increased levels of HGF. In contrast to WT HSCs, knockdown of CYLD did not change HGF levels in HDAC7-deficient HSCs, indicating the importance of CYLD-HDAC7 interaction for regulation of HGF expression in HSCs. We observed that HDAC7 was primarily localized in nuclei of HSCs, whereas stimulation with TNF or IL-6 promoted translocation of HDAC7 from the nucleus to the cytoplasm and binding to CYLD. This interaction further prevented the nuclear translocation of HDAC7 and recruitment to the HGF promoter. Consistent with this finding, it has recently been shown that TNF derepressed expression of HDAC7 target genes. 38 However, it has yet to be determined whether HDAC7 phosphorylation and binding to 14-3-3 are necessary for CYLD interaction. However, we observed a direct interaction between purified CYLD and HDAC7 protein in vitro, suggesting an alternative mechanism of HDAC7 inactivation in the cytoplasm induced through CYLD, independent of HDAC7 phosphorylation and 14-3-3 interaction.
In summary, our findings highlight a novel link between CYLD and HDAC7, offering mechanistic insight into the contribution of these proteins to the progression of liver disease. Notably, interaction between CYLD and HDAC7 occurs independently of the deubiquitin activity of CYLD and functions in the presence of proinflammatory cytokines secreted from infiltrating inflammatory cells, resident macrophages, and HSCs, activated in response to liver injury. We propose a model in which CYLD-regulated hepatic HGF expression plays a crucial role in the interaction of hepatocytes with nonparenchymal liver cells and (infiltrating) inflammatory cells, providing protection against hepatocellular injury and inflammation and, consequently, the development and progression of hepatic fibrosis (Fig.  8D) . We propose that this CYLD-regulated pathway works together with other important signaling pathways in HSCs and other cell types, including hepatocytes, KCs, and recruited inflammatory cells for restraining hepatic injury and fibrosis.
In addition, the novel CYLD-HDAC7 connection might be critical for other biological processes, considering the pleiotropic function of this HDAC under physiological and pathological conditions. Thus, these findings provide an avenue for potential strategies to selectively affect HDAC7 under inflammatory conditions, in CLDs, and, potentially, in conditions beyond hepatic disorders.
